- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00101088
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
A Phase I Study of CCI-779 in Combination With Imatinib Mesylate in Chronic Myelogenous Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
I. Determine the safety and tolerability of temsirolimus when administered with imatinib mesylate in patients with chronic myelogenous leukemia.
II. Determine potential dose-limiting toxic effects of this regimen in these patients.
III. Determine, preliminarily, hematologic and cytogenetic response rates in patients treated with this regimen.
OUTLINE: This is a multicenter, dose-escalation study of temsirolimus.
Patients receive temsirolimus intravenously (IV) over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients receive 2 additional courses beyond maximal response. Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed for survival.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- University of California Medical Center At Irvine-Orange Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed chronic myelogenous leukemia (CML)
Philadelphia chromosome-positive OR Bcr-Abl-positive disease, meeting 1 of the following criteria:
Accelerated phase, defined by at least 1 of the following:
- 10-19% blasts in the peripheral blood or bone marrow
- At least 20% basophils in peripheral blood or bone marrow
- Platelet count < 100,000/mm^3 (unrelated to therapy)
- Platelet count > 1,000,000/mm^3 (unresponsive to therapy)
- Increasing splenomegaly AND increasing WBC count (unresponsive to therapy)
- Clonal evolution
Blast phase, defined by 1 of the following:
- At least 20% blasts in peripheral blood or bone marrow
- Extramedullary disease
Chronic phase, defined by all of the following:
- Less than 10% blasts in peripheral blood or bone marrow
- Less than 20% basophils in peripheral blood or bone marrow
- Platelet count > 100,000/mm^3
- Absence of clonal evolution
May have received and/or failed prior imatinib mesylate therapy
Patients not previously treated with imatinib mesylate receive oral imatinib mesylate once daily 14 days before beginning study drug
- Must be able to tolerate 600 mg per day of imatinib mesylate before starting CCI-779
Patients with chronic phase disease must have failed prior imatinib mesylate at a dose ≥ 600 mg/day, as defined by 1 of the following:
- Must not have achieved or must have lost hematologic response within 3 months after the start of imatinib mesylate
- Must not have achieved or must have lost cytogenetic response after 6 months of treatment with imatinib mesylate
- Must not have achieved or must have lost major cytogenetic response after 12 months of treatment with imatinib mesylate
- Must have lost complete cytogenetic response
- Bone marrow aspirate and biopsy with cytogenetics and fluorescent in situ hybridization confirming t(9;22) completed within the past 28 days
- Performance status - SWOG 0-2
- More than 3 months
- See Disease Characteristics
- Bilirubin normal
- AST and ALT < 2.5 times upper limit of normal (ULN) (5 times ULN if suspected liver involvement with leukemia)
- Creatinine normal
- Creatinine clearance > 60 mL/min
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Ejection fraction ≥ 50% by echocardiogram or MUGA scan for patients with known positive cardiac history (e.g., heart failure, coronary artery disease, cardiomegaly on prior chest x-ray, or valvular heart disease)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Fasting cholesterol ≤ 350 mg/dL
- Fasting triglycerides ≤ 400 mg/dL
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to temsirolimus or imatinib mesylate
- No active or ongoing infection
- No psychiatric illness or social situation that would preclude study compliance
- No other active malignancy except nonmelanoma skin cancer
- No other uncontrolled illness
- At least 48 hours since prior interferon alfa for CML
- At least 6 weeks since prior stem cell transplantation
- No concurrent biologic agents
- No concurrent prophylactic colony-stimulating factors
- At least 24 hours since prior hydroxyurea for CML
- At least 7 days since prior mercaptopurine or vinca alkaloids for CML
- At least 7 days since prior low-dose cytarabine (< 30 mg/m^2 every 12-24 hours) for CML
- At least 14 days since prior homoharringtonine for CML
- At least 14 days since prior moderate-dose cytarabine (100-200 mg/m^2 for 5-7 days) for CML
- At least 21 days since prior anthracyclines, mitoxantrone, cyclophosphamide, etoposide, or methotrexate for CML
- At least 28 days since prior high-dose cytarabine (1-3 g/m^2 every 12-24 hours for 6-12 doses) for CML
- At least 6 weeks since prior busulfan for CML
- No concurrent hydroxyurea
- No other concurrent chemotherapy
- At least 7 days since prior steroids for CML
- No prior organ transplantation
- More than 2 weeks since prior major surgery (e.g., thoracotomy or intra-abdominal surgery)
- Recovered from all prior therapy
- Prior experimental therapy allowed provided completion of treatment corresponds to a duration > 5 half-lives of the experimental drug or any known active metabolite before study
- No concurrent cyclosporine
- No concurrent anagrelide
- No concurrent oral anticoagulants, including warfarin
- No concurrent CYP3A4 inducers or inhibitors
- No concurrent tacrolimus
- No concurrent plasmapheresis
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational agents
- No other concurrent anticancer therapies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (imatinib mesylate, temsirolimus)
Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28.
Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
|
Correlative studies
Given orally
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Unacceptable toxicity graded according to the NCI CTCAE version 3.0
Time Frame: Up to 5 years
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease progression
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Survival
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Duration of response
Time Frame: Up to 5 years
|
Presented using descriptive statistics.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tiong Ong, University of California Medical Center At Irvine-Orange Campus
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Neoplastic Processes
- Cell Transformation, Neoplastic
- Carcinogenesis
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Blast Crisis
- Leukemia, Myeloid, Accelerated Phase
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Antifungal Agents
- Imatinib Mesylate
- Sirolimus
Other Study ID Numbers
- NCI-2009-00073
- UCI-04-04
- R21CA112936 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Accelerated Phase Chronic Myelogenous Leukemia
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Children's Oncology GroupPfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...Active, not recruitingAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CMLUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)United States
-
National Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
Incyte Biosciences UKCompletedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous LeukemiaUnited Kingdom, Ireland
-
Bristol-Myers SquibbCompletedChronic Myelogenous LeukemiaNetherlands, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Singapore, Taiwan, United Kingdom, France, Korea, Republic of, Philippines, Sweden, Thailand, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzer...
-
NovartisCompletedLeukemiaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterActive, not recruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...United States
-
National Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia in Remission | Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Previously Treated Myelodysplastic Syndromes | Relapsing Chronic Myelogenous Leukemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess...United States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States